-
Part 1 | Session 2 Catheter Ablation vs. AADs for VT in Ischaemic Heart Disease
-
Part 1 | Session 3 PFA in Persistent AF – Navigating Real-World Safety Concerns
-
Part 1 | Session 4 Conduction System Pacing: Replacement or Complement to CRT?
-
Part 1 | Session 6 SAFE-PED EV-ICD Registry
-
Part 1 | Session 7 Lattice-Tip vs Irrigated-Tip Catheter for CTI Ablation: LINEAR
-
Part 1 | Session 8 TiFFANY-AF: Real-World Mortality Outcomes With PFA vs Thermal Ablation
-
Part 1 | Session 10 New VT Mapping Strategies: From Drivers to Conduction Channels
-
Part 1 | Session 11 Off-Label PFA: VT and Emerging Indications
-
Part 1 | Session 12 Are We Moving to a Single-Catheter Workflow in AF Ablation?
-
Part 1 | Session 13 EHRA 2026: Prediction, Risk Modulation and AI in Arrhythmia Management
-
Part 1 | Session 14 Integrating PFA into Contemporary AF Ablation Workflows
-
Part 1 | Session 15 Beyond PVI: Does Dual-Energy PFA Change the Way We Ablate?
-
Part 1 | Session 16 ULYSSES – Ultrasound-Guided Venous Access for Safer AF Ablation
-
Part 2 | Session 1 4 Trials That Will Change My Practice With Dr Luigi Di Biase
-
Part 2 | Session 2 6 Trials That Will Change My Practice with Prof Serge Boveda
EHRA Congress 2026 — Dr Francesco Santoro (University of Foggia, Foggia, IT) joins us to explore how electrophysiologists can approach risk assessment and decision-making when considering catheter ablation in high-risk ventricular tachycardia patients — a population where the potential benefits of ablation must be carefully weighed against procedural complexity and patient frailty.
Interview Questions:
- How do you define the "high-risk" VT patient, and what are the key characteristics that flag a case as requiring particular care?
- What does your pre-procedural risk assessment process look like, and which factors carry the most weight in your decision-making?
- How do you approach the risk-benefit conversation with patients, and what are the most important points to communicate clearly?
- What role does centre expertise and multidisciplinary input play in managing these cases, and when should referral be considered?
- Are there patients you would consider too high-risk for ablation — and if so, what are the alternatives?
- How is advancing technology — substrate mapping, epicardial access, haemodynamic support — changing what's possible in this patient group?
- What are your key take-home messages for clinicians facing these decisions in routine practice?
Recorded on-site at EHRA Congress 2026, Paris.
Editor: Jordan Rance
Videographer: David Ben-Harosh
Support: This is an independent interview produced by Arrhythmia Academy.
Watch our video collection covering late-breaking data from EHRA Congress 2026 for short, accessible Expert Interviews and Highlights of the most pertinent trials.
More from this programme
Part 1
Comments